Abstract Library

#3002 Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE

Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruszniewski P, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Neuroendocrine tumours, lanreotide,

#2212 A Rare Case of Paraneoplastic Hypercalcemia Secondary to a Neuroendocrine Pancreatic Tumour (pNET).

Introduction: Paraneoplastic hypercalcemia (HC) is a well-described affection in literature. It can relay on several mechanisms among with bone osteolysis, Parathormone (PTH) related peptide (rp) production, primary hyperparathyroidism, and Calcitriol (CT) secretion. CT secretion-mediated HC is more frequently observed among lymphomas and has only been once reported in pNET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Belaïd A, Dhenin A, Jopart P, Seront E, Grandjean M,

Keywords: paraneoplastic hypercalcemia, pancreatic neuroendocrine tumor, calcitriol,

#1654 A Single Centre Analysis of the Management of Appendiceal Neuroendocrine Neoplasms (NENs) Including Goblet Cell Carcinoids (GCC)

Introduction: Appendiceal neuroendocrine neoplasms (NENs) are usually diagnosed incidentally on histology following an appendicectomy. They include carcinoid tumours (appendiceal neuroendocrine tumours, NETs) and goblet cell carcinoids (GCC). GCC neoplasms are able to transform to an adenocarcinoma phenotype.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Sagar V, Coldham C, Shetty S, Elshafie M, Taniere P,

Keywords: Appendiceal neoplasm, neuroendocrine tumors,

#1475 Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity with Lanreotide Autogel/Depot (LAN) vs Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data

Introduction: TGR is a novel measure of tumor growth activity that may be more precise than RECIST for evaluating response to treatment of NETs.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Dromain C

Authors: Caplin M, Pavel M, Ruszniewski P, Liyanage N, Massien C,

Keywords: TGR, PFS,

#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization

Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Coriat R

Authors: Dréanic J, Lepère C, Mostafa E, Gouya H, Rougier P,

Keywords: vipoma, hepatectomy, Trans Arterial Chemo Embolization (TACE), neuroendocrine tumors (NET), vasoactive intestinal peptide (VIP), systemic chemotherapy,